Thermo Fisher Scientific Offers Financial Flexibility with New Managed Equipment Solutions

 
 

- Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced the launch of Managed Equipment Solutions a new subscription-based offering that bundles instrument and equipment procurement with consumables, applications support, software, training and extended service in a convenient and cost-efficient agreement.

 

Managed Equipment Solutions (MES) is ideal for biopharma companies, academic institutions, healthcare organizations and industrial businesses seeking innovative procurement models that offer all the benefits of premium instrument procurement but with increased flexibility. MES gives customers in research, life sciences, specialty diagnostics and applied markets the assurance of long-term, consistent analytical technology performance with predictable subscription costs and a pathway to future innovation.

 

"Managed Equipment Solutions is a direct result of our customers asking for a value-added offering that gives them convenient and timely access to our latest instrumentation and equipment innovations," said Dan Shine , senior vice president, and president of Thermo Fisher's Analytical Instruments business. "Through a predictable, fixed-budget subscription, customers can bundle premium technology with all the associated products and services required to support their workflows now, as well as in the future as their research and application needs evolve."

 

As an integrated solution, MES can reduce total cost of ownership while preserving capital budgets. Meanwhile, it protects against technology obsolescence by enabling customers to upgrade their instruments and equipment every three to five years. MES is provided through a single, easy to manage agreement, resulting in a highly streamlined procurement process.

 

For more information, please visit https://www.thermofisher.com/us/en/home/products-and-services/services/financial-leasing-services/managed-equipment-solutions.html .

 

  About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue exceeding $25 billion . Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, improving patient diagnostics and therapies or increasing productivity in their laboratories, we are here to support them. Our global team of more than 75,000 colleagues delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services and Patheon. For more information, please visit www.thermofisher.com .

 
 

  Thermo Fisher Scientific (PRNewsfoto/Thermo Fisher Scientific) 

 
 

Media Contact Information:
Charlotte McCormack  
Phone: 781-622-1202
E-mail: charlotte.mccormack@thermofisher.com  

 

 

 
 
 

 Cision View original content to download multimedia: https://www.prnewswire.com/news-releases/thermo-fisher-scientific-offers-financial-flexibility-with-new-managed-equipment-solutions-301201400.html  

 

SOURCE Thermo Fisher Scientific

 
 

News Provided by PR Newswire via QuoteMedia

The Conversation (0)
illustration of brain and cell phone.

BlinkLab Completes First Patient Test for US Autism Diagnostic Study

Digital healthcare company BlinkLab (ASX:BB1) has tested the first patient in its US autism diagnostic study, which is geared at validating the company's Dx1 test as a diagnostic aid for clinicians.

BlinkLab states in its Wednesday (March 12) release that the study is the largest digital diagnostic trial for autism in the US, with its aim being to support the early detection of developmental conditions like autism.

The first patient test took place at PriMED Clinical Research in Dayton, Ohio. PriMED, a division of PriMED Physicians, is one of two clinical sites selected for the study’s initial phase, which is targeting 100 patients.

Keep reading...Show less
HeraMED Signs Strategic Collaboration Agreement with Garmin Health

HeraMED Signs Strategic Collaboration Agreement with Garmin Health

HeraMED Limited (ASX: HMD), a medical data and technology company leading the digital transformation of maternity care, is delighted to announce it has entered into a collaboration agreement with Garmin (NYSE: GRMN), a leading global provider of smartwatches and GPS-enabled products, aimed at enhancing remote pregnancy monitoring and expanding the range of health data available to expectant mothers and their healthcare providers.

Keep reading...Show less
Cardiologist wearing virtual reality glasses.

2 Biggest Medical Device ETFs in 2025

Exchange-traded funds (ETFs) are a popular investment strategy, and generally contain a variety of publicly traded companies under one stock symbol, often with a focus on a specific sector.

Depending on the ETF, investors may be able to track up-and-coming companies, get exposure to top firms or a mix of both. Aside from stocks, some ETFs also track commodities or bonds.

In the healthcare industry, medical device ETFs bring together companies that go to great lengths to develop pharmaceutical-based technology that can improve the lives of patients.

Keep reading...Show less
Cyclomedica

Cyclopharm Signs US Agreement with HCA Healthcare for Technegas®

Cyclopharm Limited (ASX: CYC) is pleased to announce the signing of a major contract with Hospital Corporation of America Healthcare (HCA), one of the largest single healthcare providers in the United States. This agreement marks a significant milestone for the company which will allow the deployment of Technegas® in up to 169 nuclear medicine departments across HCA’s extensive network.1

Keep reading...Show less
CONNEQT App Launches in USA as Pulse Deliveries Commence

CONNEQT App Launches in USA as Pulse Deliveries Commence

Cardiex Limited (CDX:AU) has announced CONNEQT App Launches in USA as Pulse Deliveries Commence

Download the PDF here.

Female doctor with clipboard talking to smiling female patient at hospital.

Revolutionizing Women's Health: Antifungal Innovation Brings New Investment Opportunities

The intersection of women's health and antifungal innovation represents a pivotal moment in healthcare, offering both transformative medical advancements and compelling investment opportunities.

The groundbreaking developments in antifungal treatments specifically targeting women's health issues present a substantial market potential, resulting in rising investor interest in this rapidly evolving sector.

Despite comprising half the global population, women face unique health challenges that have historically received insufficient attention and investment. Among these health challenges, vaginal candidiasis stands out as a persistent and widespread issue affecting millions of women worldwide.

Keep reading...Show less

Latest Press Releases

Related News

×